In conclusion, short-term intensive therapy with basal insulin plus OHAs showed comparable benefits to CSII in terms of overall glycemic control and improvement in β-cell function in newly diagnosed patients with type 2 diabetes mellitus and is a possible option for treating newly diagnosed patients with type 2 diabetes (Journal of Diabetes Research)
Diabetes News
Glycosmedia is dedicated to bringing free, non-promotional, editorially independent news to a global audience about developments in diabetes, and is primarily aimed at health professionals.
The peripheral atherosclerotic profile in patients with type 1 diabetes mellitus warrants a thorough vascular assessment of asymptomatic patients
Peripheral artery disease is often undiagnosed in asymptomatic patients with DM1. However, its presence may change medical management in a substantial percentage of cases, highlighting the potential benefit of a thorough vascular assessment on these patients (Diabetes/Metabolism Research and Reviews)
Effect of Health Information Technologies on Glycemic Control Among Patients with Type 2 Diabetes
Our meta-analysis shows that overall, HITs have favorable impact on glycemic control of patients with type 2 diabetes. On average, mobile-based interventions produce larger effects compared to other forms of approaches under review (Current Diabetes Reports)
Pumps or Multiple Daily Injections in Pregnancy Involving Type 1 Diabetes: A Prespecified Analysis of the CONCEPTT Randomized Trial
In CONCEPTT, MDI users were more likely to have better glycemic outcomes and less likely to have gestational hypertension, neonatal hypoglycemia, and NICU admissions than pump users. These data suggest that implementation of insulin pump therapy is potentially suboptimal during pregnancy (Diabetes Care)
Fat Versus Carbohydrate-Based Energy-Restricted Diets for Weight Loss in Patients With Type 2 Diabetes
A diet with an optimal macronutrient composition remains uncertain for patients with combined T2D and obesity. Further research is still needed to define the best dietary composition that achieves the maximum benefits on weight management, glycemic control, and cardiovascular risk factors (Current Diabetes Reports)
Protocol of a cluster randomized trial to investigate the impact of a type 2 diabetes risk prediction model on change in physical activity in primary care
This pragmatic cluster randomized controlled trial will enhance our knowledge on the clinical impact of diabetes risk scores for the first time in the real-life primary health care setting (BMC Endocrine Disorders)
Comparison of the Performance of Common Measures of Weight Regain After Bariatric Surgery for Association With Clinical Outcomes
Among a large cohort of adults who underwent RYGB surgery, weight regain quantified as percentage of maximum weight lost performed better for association with most clinical outcomes than the alternatives examined. These findings may inform standardizing the measurement of weight regain in studies of bariatric surgery(JAMA)
Effect of Intensive Glycemic Control on Risk of Lower Extremity Amputation
In type 2 diabetics, IGC was associated with a reduction in the risk for LEA. After 3.7 years of IGC there was an enduring protective effect against LEA. Improved glycemic control was a strong predictor of decreased risk for subsequent LEA. This study suggests that tight glycemic control, even over a short time period, has potential to reduce risk of limb loss (Journal of the American College of Surgeons)
Excess mortality in Finnish diabetic subjects due to alcohol, accidents and suicide: a nationwide study
The findings from this large nationwide cohort indicate higher mortality attributable to suicide, alcohol-related causes and accidents among diabetic patients than among the non-diabetic population. The results emphasize the importance of effective psychosocial interventions among high-risk diabetic patients (EJE)
Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial
The dual GIP and GLP-1 receptor agonist, LY3298176, showed significantly better efficacy with regard to glucose control and weight loss than did dulaglutide, with an acceptable safety and tolerability profile. Combined GIP and GLP-1 receptor stimulation might offer a new therapeutic option in the treatment of type 2 diabetes (The Lancet)
Psychosocial benefits of insulin pump therapy in children with diabetes type 1 and their families: The pumpkin multicenter randomized controlled trial
CSII has substantial psychosocial benefits. PROs demonstrate these benefits (Pediatric Diabetes)
Glycaemic variability assessed by continuous glucose monitoring and the risk of diabetic retinopathy in latent autoimmune diabetes of the adult and type 2 diabetes
GV is more strongly associated with DR in type 2 diabetes than in LADA, suggesting that different glucose‐lowering strategies should be adopted for these two types of diabetes (Journal of Diabetes Investigation)
Treatment with incretins does not increase the risk of pancreatic diseases compared to older anti‐hyperglycaemic drugs, when added to metformin
Real world evidence in people with Type 2 diabetes (Diabetic Medicine)
Effects of intensive interventions compared to standard care in people with type 2 diabetes and microalbuminuria on risk factors control and cardiovascular outcomes
Apart from blood pressure outcomes, there was no evidence that intensive interventions improve or worsen HbA1c, total cholesterol, LDL, triglycerides, urinary albumin excretion rate, risk of cardiovascular or mortality outcomes in people with type 2 diabetes and microalbuminuria (Diabetes Research and Clinical Practice)
Correlation Between Different Stages of Diabetic Nephropathy and Neuropathy in Patients with T2DM
The results suggest that diabetic nephropathy is closely associated with the development of DPN in T2DM patients and that UAER and disease duration can be used as warning indicators of DPN progression (Diabetes Therapy)
Management of Hyperglycemia in Type 2 Diabetes, 2018
A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Standards of Medical Care in Diabetes—2018
16 sections (Diabetes Care)
Boehringer Ingelheim and Lilly present full results of Tradjenta®’s CARMELINA® cardiovascular outcome trial
The overall safety profile of Tradjenta in the trial, including adults with kidney disease, was consistent with previous data and no new safety signals were observed
Boehringer Ingelheim and Lilly present full results from EASE Phase III program for empagliflozin as adjunct to insulin in type 1 diabetes
Full results presented at the 54th European Association for the Study of Diabetes Annual Congress (EASD)
Role of Tight Glycemic Control during Acute Coronary Syndrome on CV Outcome in Type 2 Diabetes
In conclusion, optimal glucose target levels and treatment regimens in this setting of patients are still under debate. Future studies on intensive glucose control must be developed to reduce both glucose variability and risk of hypoglycemia, thus achieving an optimal blood glucose concentration in critically ill patients, particularly in ACS (Journal of Diabetes Research)
- 1
- 2
- 3
- …
- 168
- Next Page »
Glycosmedia is also available as an App: